Pfizer Limited

NSE: PFIZER

Healthcare Healthcare

₹3,808.7

-0.14%EOD · 19 Oct

Pfizer Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹17,424 Cr

52W Range

₹5446 / ₹3731

Volume

15K

49.4% delivery

1Y Return

-28.6%

P/E Ratio

23.7

P/B Ratio

4.2

ROE

17.2%

Debt / Equity

1.67

Peers in Healthcare

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Pfizer Limited(this stock)	₹3,808.7	₹17,424 Cr	23.7	4.2	17.2%	1.97%
Divi's Laboratories LimitedDIVISLAB	₹9,087	₹2.41 L Cr	83.0	14.5	16.2%	0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM	₹4,558.7	₹1.73 L Cr	72.8	18.4	17.0%	0.83%
Laurus Labs LimitedLAURUSLABS	₹2,069	₹1.12 L Cr	101.8	21.0	17.7%	0.12%
Zydus Lifesciences LimitedZYDUSLIFE	₹1,113.9	₹1.11 L Cr	25.0	4.2	18.3%	0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP	₹7,700	₹1.11 L Cr	54.3	12.0	21.5%	0.25%
Aurobindo Pharma LimitedAUROPHARMA	₹1,621.4	₹93,292 Cr	26.1	2.6	9.9%	0.00%
Mankind Pharma LimitedMANKIND	₹2,253.2	₹93,067 Cr	46.0	5.8	12.4%	0.00%
Max Healthcare Institute LimitedMAXHEALTH	₹830	₹80,785 Cr	56.7	7.7	14.3%	0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice

50/100

Composite score: 40% quality, 30% valuation, 30% momentum

QualityGood · 68

ValuationGood · 65

MomentumPoor · 10

In confirmed downtrend (Stage 4)

Technical Indicators

Full analysis · objective math, not advice

Returns

-0.1%

-1.6%

-5.1%

-16.8%

-23.2%

-28.6%

Weinstein Stage

Stage 4 — Declining (downtrend)

RSI (14)

40 Neutral

Trend Template

0/7weak

RS vs Nifty (3M)

-12.6pp

Moving Averages (price vs MA)

20-DMA

₹3904

below

50-DMA

₹4330

below

150-DMA

₹4564

below

200-DMA

₹4636

below

From 52W High

-31.7%

From 52W Low

+2.1%

Support (20D)

₹3731

Resistance (20D)

₹4124

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.